Raleigh, N.C., March 28 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR), a medical tissue adhesive products company, today announced
that it is initiating a clinical study for LIQUIDERM(TM) Liquid Healing
Bandage for the treatment of minor cuts and abrasions. Results from the
clinical study will be used in an anticipated 510(k) submission to the FDA.
LIQUIDERM(TM) Liquid Healing Bandage would compete in the over-the-counter
adhesive bandage category, which exceeds $800 million in worldwide sales.
"The start of the definitive clinical trial for LIQUIDERM(TM) Liquid
Healing Bandage represents a major step in the development of a
transformational innovation for Closure Medical", said Robert V. Toni,
President and CEO. "We believe our unique adhesive technology could fulfill
needs not being met by any adhesive bandage currently on the market."
Preliminary animal studies have shown that LIQUIDERM(TM) Liquid Healing
Bandage creates a moist wound-healing environment and provides a barrier to
infection for minor cuts and abrasions. "A moist wound healing environment
promotes improved healing of minor cuts and abrasions," said Dr. William
Eaglstein, professor and chairman of the Department of Dermatology and
Cutaneous Surgery at the University of Miami School of Medicine.
Mr. Toni continued, "LIQUIDERM(TM) Liquid Healing Bandage is unlike
existing adhesive bandages. It creates a long lasting healing environment
that requires only one application. It conforms exactly to any wound size
providing superior protection from dirt and germs. Additionally, the flexible
film stays on bending and moving parts of the body even in water."
The 160 patient multi-center study will be conducted at the University of
Miami under the direction of Dr. Eaglstein, the Orlando Regional Healthcare
System by Dr. Philip Giordano, the Palm Beach Research Center under Dr. Barry
Miskin, and the Skin Study Center by Dr. James Leyden.
CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina,
develops, manufactures and commercializes medical tissue adhesive products
based on its proprietary cyanoacrylate technology. CLOSURE's nonabsorbable
tissue adhesive products may be used to replace sutures and staples for
certain topical wound closure applications, while its internal tissue adhesive
products, once approved and marketed, could potentially be used for internal
wound closure and management. Currently marketed nonabsorbable tissue
adhesive products include DERMABOND(R)* Topical Skin Adhesive, which is used
to replace sutures and staples for closure of certain lacerations and
incisions, OCTYLDENT(R)* adhesive, which is used as an adjunct in the
treatment of adult periodontal disease, and the NEXABAND(R)* line of topical
adhesives, which are used in veterinary wound closure and management.
* DERMABOND(R) is a trademark of Ethicon, Inc.; SOOTHE-N-SEAL, LIQUIDERM,
OCTYLDENT and NEXABAND are all trademarks of CLOSURE Medical Corporation.
To receive CLOSURE's latest news release and other corporate documents via
fax, at no cost, call 1-800-PRO-INFO, use the Company's symbol CLSR. Or visit
the Financial Relations Board's website at http://www.frbinc.com .
This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements. These factors
include, but are not limited to the early stage of commercialization of the
Company products; the progress of its research and development programs for
future products; the need for regulatory approval and effects of governmental
regulation; technological uncertainties; dependence on marketing partners, and
dependence on patents and trade secrets, as well as those detailed in the
Company's Annual Report on Form 10-K for the year ended December 31, 1998
filed with the Securities and Exchange Commission.
SOURCE CLOSURE Medical Corporation
 back to top
Related links:
http://www.frbinc.com
CONTACT:
Robert V. Toni, President & CEO, or J. Blount
Swain, CFO, both of CLOSURE Medical Corporation, 919-876-7800, or
General Info, Paul G. Henning, Analysts, Cecelia Heer, or Media
Info, Deanne Eagle, all of The Financial Relations Board,
212-661-8030
|
